Combination of the mTOR inhibitor ridaforolimus and the anti-IGF1R monoclonal antibody dalotuzumab: preclinical characterization and phase I clinical trial.
Clinical cancer research : an official journal of the American Association for Cancer Research.
Times cited: 18
- Discovery of biomarkers predictive of GSI response in triple-negative breast cancer and adenoid cystic carcinoma. Cancer discovery. 2014 Academic Article GET IT